Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

Ehsan Rahimy, MD; David G. Miller, MD, Michael Klufas, MD, discusses how real-world treatment strategies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.